Form 4: BioLife Solutions EVP & Chief Scientific Officer Sells Shares for Tax Obligations

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, sold 536 shares of common stock on July 7, 2025, as part of a pre-arranged 10b5-1 plan to cover tax withholding from restricted stock vesting.

Summary

• Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), reported a sale of common stock.
• On July 7, 2025, 536 shares of common stock were sold at a price of $22.27 per share.
• The transaction was executed under a Rule 10b5-1(c) trading plan, which became effective on January 3, 2023.
• The purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following this transaction, Aby J. Mathew directly beneficially owns 352,582 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine, pre-planned sale for tax purposes, which is generally considered neutral in terms of market sentiment. It does not indicate a change in management's confidence or strategic direction.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, non-discretionary transaction.
• The sale was specifically for satisfying tax withholding obligations, not a discretionary sale of shares.
• The reporting person retains a significant beneficial ownership of 352,582 shares after the transaction.

Negatives

• A sale of shares by an executive, even for tax purposes, reduces their direct equity stake in the company.

Risks

• While the sale is for tax purposes, any insider sale could be misinterpreted by the market as a lack of confidence, though this is less likely for a tax-related 10b5-1 sale.

Future Outlook

NA

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes and does not provide broader industry context or trends.

Stakeholder Impact

• The sale of a small number of shares for tax purposes by an executive is unlikely to have a significant direct impact on shareholders, employees, customers, suppliers, or creditors. It is a routine administrative transaction.

Key Dates

Keywords

BioLife Solutions, BLFS, Form 4, Insider Trading, Stock Sale, Executive Compensation, Rule 10b5-1, Tax Withholding, Restricted Stock, Aby J. Mathew